Insulin delivery devices market seen reaching $74.39 billion by 2035

Market Research Future projects the global insulin delivery devices market will nearly double from 2026 to 2035, driven by rising diabetes rates, wider reimbursement and faster adoption of connected, automated delivery systems. The forecast points to growing demand for pens, pumps and wearable platforms across homecare, hospitals and pharmacies.

Why it matters: - The market is being pulled by a larger diabetes patient base that needs ongoing insulin administration. - Wider reimbursement for wearable and automated devices could lower cost barriers and speed adoption. - The shift toward connected delivery systems may improve dosing, monitoring and remote care for patients and clinicians.

What happened: - Market Research Future projected the global insulin delivery devices market will reach USD 74.39 billion by 2035. - The market is forecast to rise from USD 36.15 billion in 2026. - The forecast implies an 8.35% CAGR from 2026 to 2035. - The market size was estimated at USD 34.15 billion in 2025. - The report was released Aug. 11, 2026.

The details: - Rising diabetes prevalence is expanding long-term demand for pens, syringes, pumps, infusion sets and connected delivery platforms. - Type 1 diabetes requires lifelong insulin therapy, and many people with Type 2 diabetes eventually need insulin to maintain glycemic control. - More diagnoses, longer life expectancy and more home-based diabetes care are supporting demand for portable self-management tools. - Reimbursement is expanding for tubeless patch-style and wearable systems, making advanced devices more accessible. - Public procurement in emerging markets is helping widen access and increase device volumes. - Bluetooth-enabled pens, connected pumps, tubeless patch systems and hybrid automated platforms are replacing older workflows in parts of the market. - These systems can send glucose and dosing data to mobile apps and clinical systems for review and treatment adjustment. - Request a free sample: Request a free sample - Ask for customization: Ask for customization - Read detailed insights: Read the full report

Between the lines: - The market is moving away from basic injection hardware and toward devices that combine convenience, connectivity and decision support. - Reimbursement and payer policy are becoming as important as product design in driving adoption. - Competition is increasingly centered on software, algorithms, CGM integration, interoperability and recurring consumables revenue rather than hardware alone. - The top five players are projected to hold about 55% to 62% of global revenue, which points to a concentrated market.

What's next: - Pen-based devices are expected to remain the largest product category, with about 48% revenue share in 2025. - Insulin pumps are the fastest-growing product type, with a projected 12.4% CAGR through 2035. - Connected devices are the fastest-growing technology category, with a projected 13.8% CAGR through 2035. - Adults remain the largest patient group, while pediatrics is the fastest-growing age segment. - North America stays the largest regional market, while Asia-Pacific is forecast to be the fastest-growing region at 9.9% CAGR through 2035. - By the early 2030s, insulin delivery is expected to become more software-defined and more closely tied to continuous glucose monitoring, mobile apps, electronic health records and telehealth. - Algorithm-driven autonomous dosing and next-generation closed-loop systems are expected to capture more premium pricing as regulation and evidence mature.

The bottom line: - The insulin delivery devices market is entering a high-growth phase where reimbursement, connectivity and automation are reshaping who buys, what they buy and how care is delivered.